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Whole-Genome Analyses of Enterococcus faecium Isolates with Diverse
Daptomycin MICs
Lorena Diaz,a Truc T. Tran,b,c Jose M. Munita,b,d William R. Miller,b Sandra Rincon,a Lina P. Carvajal,a Aye Wollam,e Jinnethe Reyes,a,b
Diana Panesso,a,b Natalia L. Rojas,a Yousif Shamoo,f Barbara E. Murray,b George M. Weinstock,e* Cesar A. Ariasa,b
Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogotá, Colombiaa; Department of Internal Medicine, Division of Infectious Diseases,
University of Texas Medical School at Houston, Houston, Texas, USAb; University of Houston College of Pharmacy, Houston, Texas, USAc; Department of Medicine, Clínica
Alemana de Santiago, Universidad del Desarrollo, Santiago, Chiled; The Genome Institute, Washington University at St. Louis, St. Louis, Missouri, USAe; Department of
Biochemistry and Cell Biology, Rice University, Houston, Texas, USAf
Daptomycin (DAP) is a lipopeptide antibiotic frequently used as a “last-resort” antibiotic against vancomycin-resistant Entero-
coccus faecium (VRE). However, an important limitation for DAP therapy against VRE is the emergence of resistance during
therapy. Mutations in regulatory systems involved in cell envelope homeostasis are postulated to be important mediators of DAP
resistance in E. faecium. Thus, in order to gain insights into the genetic bases of DAP resistance in E. faecium, we investigated
the presence of changes in 43 predicted proteins previously associated with DAP resistance in enterococci and staphylococci us-
ing the genomes of 19 E. faecium with different DAP MICs (range, 3 to 48g/ml). Bodipy-DAP (BDP-DAP) binding to the cell
membrane assays and time-kill curves (DAP alone and with ampicillin) were performed. Genetic changes involving two major
pathways were identified: (i) LiaFSR, a regulatory system associated with the cell envelope stress response, and (ii) YycFGHIJ, a
system involved in the regulation of cell wall homeostasis. Thr120¡Ala and Trp73¡Cys substitutions in LiaS and LiaR, respec-
tively, were the most common changes identified. DAP bactericidal activity was abolished in the presence of liaFSR or yycFGHIJ
mutations regardless of the DAP MIC and was restored in the presence of ampicillin, but only in representatives of the LiaFSR
pathway. Reduced binding of BDP-DAP to the cell surface was the predominant finding correlating with resistance in isolates
with DAP MICs above the susceptibility breakpoint. Our findings suggest that genotypic information may be crucial to predict
response to DAP plus-lactam combinations and continue to question the DAP breakpoint of 4g/ml.
The surge of Enterococcus faecium as an important nosocomialpathogen has been associated with an expanding pandemic
caused by a hospital-associated (HA) genetic clade (1, 2). Indeed,
isolates belonging to this genetic lineage are frequently multidrug
resistant (MDR) with high MICs of ampicillin and vancomycin
(3). Daptomycin (DAP) is a cell membrane (CM)-targeting lipo-
peptide that has in vitro bactericidal activity against MDR E. fae-
cium and, due to the paucity of other bactericidal options, is often
used as first-line therapy despite lacking U.S. Food and Drug Ad-
ministration approval for these organisms. However, one of the
major problems when using DAP against enterococci is the emer-
gence of resistance during therapy (4–6).
Themechanisms of DAP resistance in enterococci are not fully
understood, but recent evidence suggests that there are several
genetic pathways involved and that resistance results from a se-
quential and ordered mutational pathway (7–9). In Enterococcus
faecalis, we have previously shown that emergence of resistance
during therapy involves substitutions in three proteins: (i) LiaF, a
member of the three-component regulatory systemLiaFSRwhich,
inBacillus subtilis and other Gram-positive bacteria (10), has been
shown to orchestrate the cell envelope response to stress; (ii)
GdpD, a glycerophosphoryl-diester phosphodiesterase, involved
in phospholipid metabolism; and (iii) Cls, a cardiolipin synthase
(11). Themechanism ofDAP resistance inGram-positive bacteria
was initially postulated to involve repulsion of the calcium-deco-
rated DAP from the cell surface (12). However, we recently pro-
vided evidence that DAP resistance in an E. faecalis strain was due
to diversion of DAP from the division septum associated with
redistribution of CM cardiolipin (CL)microdomains, without re-
pulsion of DAP from the cell surface (8). Of note, deletion of Ile at
position 177 of LiaF was sufficient for membrane remodeling and
also abolished DAP in vitro bactericidal activity (8, 13).
Genomic analyses in E. faecium, using clinical-strain pairs of
DAP-susceptible and DAP-resistant isolates recovered during
therapy, have identified many genetic changes associated with
DAP resistance (14, 15), but the specific role of each of these mu-
tations remains to be established. Interestingly, in a collection of
clinical E. faecium isolates recovered from bacteremia, ca. 75% of
DAP-“susceptible” isolates with MICs close to the established
breakpoint (4 g/ml) harbored changes in LiaFSR (16). Further-
more, recent data suggest that the combination of DAP with cer-
tain -lactams (e.g., ampicillin and ceftaroline) restores DAP ac-
tivity in vitro and in vivo by increasing the ability of the antibiotic
to bind to its CM target (17–20, 41), but themechanism or genetic
basis for such synergism is unknown. Therefore, in an attempt to
dissect the genetic determinants implicated in DAP resistance in
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E. faecium and the interaction with -lactams, we used whole-
genome sequencing of a collection of 19 unrelated clinical isolates
of E. faecium with a diverse range of DAP MICs and investigated
the presence of genetic changes in 43 predicted proteins previ-
ously associated with DAP resistance. Note that, although the ac-
cepted term is “DAP nonsusceptibility,” we use the term “DAP
resistance” throughout for ease of presentation.
(Parts of the results of this study were presented at the 53rd
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, September 10 to 13, 2013, Denver, Colorado, USA.)
MATERIALS AND METHODS
Bacterial isolates, molecular typing, and MIC determinations.A total of
19 clinical strains of E. faecium were included in the present study (DAP
MICs, 3 to 48 g/ml) (Table 1). We included 17 U.S. isolates from differ-
ent patients and submitted to reference laboratories from diverse geo-
graphical areas. In addition, there were two E. faecium strains recovered in
South America (21) before the introduction of DAP to the region (Table
1). Typing of isolates was performed using in silico multilocus sequence
typing (MLST) analysis derived from the genomic sequence. Determina-
tion of DAP MICs was performed by Etest (bioMérieux, Marcy l’Etoile,
France) onMueller-Hinton agar according to themanufacturer’s instruc-
tions. Etest was used for DAP since our goal was to detect small variations
in DAP MICs. The MICs for each strain were determined in triplicate.
Two independent observers read the results, and a third investigator was
consulted whenever a disagreement was identified. MICs of other antibi-
otics were determined by an agar dilution method (22).
Genome sequencing and mutational analysis. Whole-genome anal-
ysis, genomic assemblies, and annotation were performed as described
previously (15). A total of 43 predicted proteins (Fig. 1; see also Table S1 in
the supplemental material) were included in the analysis representing
genes previously associatedwithDAP resistance in enterococci (11, 14, 15,
23) and E. faecium homologues of six genes associated with DAP resis-
tance in S. aureus (mprF, pgsA, and the dlt cluster; see Tables S2 and S3 in
the supplemental material) (24–27). A relevant change was defined as a
nucleotide change that resulted in an amino acid substitution that was not
present at the sameposition on the predicted protein sequences of otherE.
faecium genomes publicly available (independent of the DAP MIC). Se-
quence comparisons were performed using the multiple sequence align-
ment program ClustalW2 and E. faecium DO (TX16), a DAP-susceptible
(MIC 2g/ml) clinical strain (whose genome is sequenced and closed)
(28, 29), as the template to refine comparisons. All accession numbers are
shown in Table 1.
Time-kill assays and evaluation of synergism between ampicillin
(AMP) and DAP. To assess the bactericidal activity of DAP against E.
faecium, we used time-kill assays with two representative isolates of each
of the two most common genetic pathways identified displaying/or with
DAP MICs below and above the susceptibility breakpoint (4 g/ml), re-
spectively, as follows: (i) 503 and R497 (LiaFSR pathway representatives)
withMICs of 3 and 16g/ml, respectively (11), and (ii) 515 andR446 (15)
(YycFGHIJ pathway) with MICs of 3 and 16 g/ml, respectively. E. fae-
cium DO (MIC 2 g/ml) was used as a control for these experiments.
Time-kill assays were performed with an initial bacterial inoculum of 107
CFU/ml in Mueller-Hinton broth (MHB) supplemented with calcium
(50 mg/liter). DAP was added at concentrations of 5 the MIC of each
strain, and bacterial counts were performed at 0, 6, and 24 h. Antibiotic
carryover was controlled by centrifugation (bacterial cell suspensions
[1-ml samples] were centrifuged, and the pelleted bacteria were sus-
pended in the same volume of 0.9% saline solution before plating) as
described earlier (13, 30, 31). Bactericidal activity was defined as a 3
log10 reduction in CFU/ml at 24 h in comparison to the initial inoculum.
The limit of detection was 200 CFU/ml, assuming maximum plating effi-
ciency.We also tested the ability of AMP (64g/ml) to achieve synergistic
activity when combined with DAP against the same strains. Synergism
was defined as a decrease of2 log10 CFU/ml in bacterial counts at 24 h
compared to themost active single agent alone. All assays were performed
in triplicate.
BODIPY-labeled daptomycin (BDP-DAP) assays. We used BDP-
DAP to assess the interaction of DAP with the bacterial CM, as described
TABLE 1 E. faecium strains included in this studya
Strain
MIC (g/ml)b
van gene MLST BioProject accession numbers
Source or
referenceVAN TEI DAP AMP
503 256 32 3 64 vanA 280 PRJNA181868 This study
504 1 0.12 4 64 649 PRJNA181867 This study
505 1 0.12 6 64 SLVc ST39 PRJNA181866 This study
506 256 64 6 64 vanA 18 PRJNA181865 This study
509 256 0.25 4 64 vanB 17 PRJNA181864 This study
510 1 0.12 4 64 18 PRJNA181863 This study
511 1 0.25 8 64 17 PRJNA181862 This study
513 1 0.25 4 64 736 PRJNA181861 This study
514 1 0.25 8 64 17 PRJNA181860 This study
515 0.5 0.5 3 64 549 PRJNA181859 This study
S447 256 16 3 64 vanA 203 PRJNA181832 11, 15
R446 16 4 16 64 vanA 203 PRJNA181838 11, 15
R501 256 8 32 64 vanA 17 PRJNA181833 11
R494 1 0.12 48 64 664 PRJNA181837 11
R496 1 0.25 32 64 412 PRJNA181836 11
R497 1 0.25 16 64 752 PRJNA181835 11
R499 256 8 48 64 vanA 412 PRJNA181834 11
V689 256 64 4 64 vanA 736 PRJNA181831 21
P1190 256 128 3 64 vanA 125 PRJNA181840 21
a All strains (except S447 and R446, which were isolated from the same patient) had no epidemiological relationship between them and were recovered at different time points and
geographical areas in the United States. Isolates V689 and P1190 were recovered in Venezuela and Peru, respectively, before DAP was introduced in these countries. The pulsed-
field gel electrophoresis patterns of all strains were different and categorized as unrelated (data not shown).
b VAN, vancomycin; TEI, teicoplanin; DAP, daptomycin; AMP, ampicillin.
c SLV, single locus variant.
Diaz et al.
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before (8). The assays were performed using isolates 503, R497, R446, and
515 (representatives of the most common mutational pathways [see
above]). The protocol for BDP-DAP staining followed techniques previ-
ously described (7, 8, 32, 33). Briefly, isolates were grown in Luria-Bertani
(LB) broth at 37°C and incubated with BDP-DAP at two concentrations
(4 and 64 g/ml in LB broth supplemented with Ca2 at 50 mg/liter) for
10 min in darkness. Fluorescence was assessed using a standard fluores-
cein isothiocyanate filter set (excitation at 490 nm and emission at 528
nm). A minimum of two independent experiments was performed for
each strain on different days. In order to estimate the amount of BDP-
DAP bound to E. faecium strains, the fluorescence intensity was quanti-
tated and normalized to protein concentration of the samples, as de-
scribed previously (8).
RESULTS
Changes in genes involved in cell envelope homeostasis. We
sought to identify substitutions in 43 predicted proteins previ-
ously associated with DAP resistance in enterococci and staphylo-
cocci within unrelated E. faecium isolates exhibiting a diverse
range of MICs (3 to 48 g/ml). The “control” strain for our
genomic comparisons was E. faeciumDO (28, 29), a DAP-suscep-
tible clinical isolate (DAP MIC 2 g/ml) whose genome has been
sequenced and closed. The changes are shown in Fig. 1 and are
summarized according to their frequency in Table S3 in the sup-
plemental material. The most common genes affected were those
encoding regulatory systems involved in cell envelope homeosta-
sis, liaFSR and/or yycFG (including the accessory genes yycHIJ).
Indeed, 10 isolates with DAP MICs 3 g/ml harbored changes
in LiaFSR, with the most common substitutions found in LiaS
(the putative histidine kinase of the system [n 9]), followed by
the response regulator LiaR (n 7) (Fig. 1; see also Table S3 in the
supplemental material). A T120A substitution was often identi-
fied in LiaS (n  7), and W73C was found in all isolates (n  7)
with changes in LiaR. Moreover, LiaST120A was always present in
isolates harboring LiaRW73C, suggesting that these substitutions
might have coevolved. Of note, mutations in liaF, which was pre-
viously associatedwithDAP resistance in E. faecalis, were found in
four isolates, and each predicted change was unique (Fig. 1; see
Table S3 in the supplemental material). Three of these isolates
(DAPMICs of 4, 6, and 48g/ml) also harbored changes in LiaSR,
and the remaining isolate (MIC of 32 g/ml) harbored an I142T
substitution in LiaFwithout concomitant changes in LiaRS. Over-
all, alterations in LiaFSR were identified in 50% (5 of 10 isolates)
FIG 1 Amino acid changes in 43 predicted proteins associated with DAP resistance in E. faecium isolates. Black squares indicate the presence of amino acid
changes. Cls, cardiolipin synthase; GdpD, glycerophosphodiester phosphodiesterase; Cfa, cyclopropane-fatty-acyl-phospholipid synthase; PTS-EIIA, phospho-
transferase system, phosphoenolpyruvate-dependent sugar EIIA 2; SulP, sulfate transporter; XpaC, 5-bromo-4-chloroindolyl phosphate hydrolysis protein;
RrmA, rRNA (guanine-N1-)-methyltransferase A; PTS-IIA, PTS system fructose IIA component; PspC, phage shock protein C; LepB, signal peptidase I; Aad,
aldehyde-alcohol dehydrogenase; NrdR, nicotinamide mononucleotide transporter; PTS IID, mannose/fructose/sorbose transporter subunit IID; EzrA, septa-
tion ring formation regulator; RpeS-5S, ribosomal protein S5; BrnQ, branched-chain amino acid transport protein; RpoN, RNA polymerase sigma factor 54;
TelA, telurite resistance protein; MprF, lysylphosphatidylglycerol synthetase; PgsA, CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase.
Daptomycin Resistance in Enterococcus faecium
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with MICs between 3 and 4 g/ml and in 50% (5 of 10) with
MICs  4 g/ml (Fig. 1; see Table S3 in the supplemental mate-
rial). Among seven isolates harboring mutations in the YycFGHIJ
system, the most commonly involved proteins were YycH, a pu-
tative signal transduction protein (n 3), followed by YycG (sen-
sor histidine kinase of the system [n  2]) and YycI, a putative
regulatory protein (n  2) (15, 34, 35). Three isolates harbored
mutations in both LiaFSR and YycFGHIJ systems concomitantly,
suggesting that these two systems may interact to develop DAP
resistance in some isolates.
Substitutions in phospholipid metabolism enzymes. Wehad
previously postulated that changes in enzymes involved in phos-
pholipid metabolism were likely to appear at latest stages of the
DAP resistance pathway in E. faecalis (8, 9). Interestingly, after
genes predicted to function in cell envelope homeostasis, the
most common gene affected was cls (n  7), encoding a CL
synthase involved in the last committed step of synthesis of CL
from the precursor phosphatidylglycerol. The predicted amino
acid changes were located in the phospholipase D domains (PLD1
and PLD2) and in the linker region joining the two putative trans-
membrane helices, as previously described (36). Of note, Cls sub-
stitutions were found mostly in isolates with high DAP MIC (4
g/ml [n  6]) and only in one isolate with an MIC of 4 g/ml
(Fig. 1; see Table S3 in the supplemental material). Moreover, the
changes in Cls were always observed in isolates that also had
changes in one of the above-mentioned regulatory systems
(LiaFSR or YycFG), supporting our previous hypothesis that Cls
substitutions follow initial changes in cell envelope homeostasis
and “enhance” the resistance phenotype (9). Other less frequent
changes found in enzymes involved in phospholipid metabolism
were (i) in the homolog ofMprF (a lysylphosphatidylglycerol syn-
thetase [n  2]) (25, 37); (ii) Cfa, a putative cyclopropane fatty
acid synthase (n  2) (38); and (iii) GdpD a glycerophosphoryl-
diester phosphodiesterase (n 2) (11) (Fig. 1; see Table S3 in the
supplemental material).
Other, less frequent mutations. A total of five isolates with
MICs between 4 and 48 g/ml exhibited amino acid changes in a
protein of unknown function that harbors an HD domain, which
designates a superfamily of enzymes that possess phosphohydro-
lase activity and may be involved in nucleic acid metabolism and
signal transduction (39). Four strains (MICs  4 and 32 g/ml)
showed changes in the 23S rRNA methyltransferase, RrmA (40).
In addition, three isolates exhibited substitutions in TelA, a puta-
tive tellurite resistance protein (Fig. 1; see also Table S3 in the
supplemental material), previously associated with DAP resis-
tance in E. faecalis (23). Changes in TelA, RrmA, and in the HD
domain protein were always identified in conjunction with sub-
stitutions in LiaFSR or YycFGHIJ. Other genes altered less com-
monly are shown in Fig. 1 and in Table S3 in the supplemental
material. Of note, we were unable to identify any changes in pre-
dicted proteins associated with DAP resistance in two DAP-resis-
tant isolates (both with MICs of 8 g/ml) (Fig. 1), indicating that
additional genetic pathways leading to DAP resistance in E. fae-
cium remain to be identified.
Mutational pathways influence in vitro bactericidal activity
of DAP. Our previous work (8, 9, 11, 13, 15, 16) and the current
genomic analysis indicate that LiaFSR and/or YycFGHIJ are the
two most common genetic pathways resulting in DAP resistance.
Our previous studies in E. faecalis indicated that a single liaFmu-
tation abolished the in vitro bactericidal activity of DAP (DAP-
tolerant phenotype) (13) but did not increase the MIC above the
breakpoint. Thus, we examined the bactericidal activity of DAP
against E. faecium 503 (Table 1), a DAP-susceptible isolate (MIC 3
g/ml) that harbors LiaRW73C and LiaST120A. Figure 2A shows that
DAP (5 the MIC) lacked bactericidal activity against E. faecium
503 with reductions of 1 log10 CFU/ml at 24 h. A similar effect
was observed against E. faecium R497 (Fig. 2B), a DAP-resistant
(16 g/ml) isolate also carrying LiaRW73C and LiaST120A but no
changes in YycFGHIJ. Interestingly, for both 503 and R497, DAP
bactericidal activity was restored by adding AMP (64 g/ml), an
observation consistent with previous reports (18, 41). Next, we
sought to test the in vitro bactericidal activity of DAP in two rep-
resentative isolates altered in the YycFG pathway (515 and R446)
with MICs of 3 and 16 g/ml, respectively. As expected, DAP did
not have any killing effect against R446 (Fig. 2C) but also lacked
bactericidal activity against 515 which has anMIC within the sus-
ceptible range (Fig. 2D). However, in contrast to representatives
with LiaFSR changes, addition of AMP (64g/ml) to DAP had no
synergistic effect, suggesting that an altered YycFGHIJ system is
not affected by the combination of DAP and -lactams. For the
DAP-susceptible strain TX16/DO, both DAP and AMP exhibited
bactericidal activity (Fig. 2E).
Lack of DAP binding to the cell surface is the predominant
mechanism of DAP resistance in E. faecium. Two main mecha-
nisms of DAP resistance have been postulated in enterococci: (i)
electrostatic “repulsion” of calcium-decorated DAP (positively
charged) from the cell surface due to amore positively charged cell
envelope (23) and (ii) “diversion” of DAP from the division sep-
tum (the main DAP cell target) (only described in E. faecalis) (8).
In order to gain insights into the mechanism of DAP resistance
and the genetic background, we used fluorescent BDP-DAP to
study the interactions of the antibiotic with the CM in represen-
tative strains of the LiaFSR or YycFGHIJ pathways, as described
earlier (8). We used DAP-susceptible E. faecium DO (MIC  2
g/ml) as the control and performed the assays with two BDP-
DAP concentrations (4 and 64 g/ml) since DAP binding to the
cell membrane target is concentration dependent (7, 8). Figure 3
shows that binding of BDP-DAP was significantly decreased with
the DAP-resistant strains R497 (LiaFSR pathway) and R446
(YycFGHIJ pathway) at low and high concentrations compared to
the control (E. faecium DO), suggesting that antibiotic “repul-
sion” may play a prominent role in resistance. In contrast, the
pattern of BDP-DAP binding at low concentrations was similar to
that of DO for DAP-susceptible (MIC  3 g/ml) 503 (with Li-
aFSR changes) and 515 (altered YycFGHIJ) (Fig. 3). However, at
high BDP-DAP concentrations (64 g/ml), 515 had significantly
less binding to the cell membrane than DO, whereas no statisti-
cally significant difference in BDP-DAP binding was observed be-
tween 503 (LiaFSR pathway) versus DO. Our results suggest that
diversion (rather than repulsion) may be the mechanism for de-
creasedDAP killing with this isolate; however, further analyses are
required to corroborate this hypothesis.
DISCUSSION
Using genomic analyses of clinical isolates with a wide variety of
DAPMICs, we investigated the genetic basis of DAP resistance in
E. faecium. Our findings suggest that two regulatory systems are
likely to be involved in development of DAP resistance in E. fae-
cium: (i) LiaFSR, which has been associated with the cell envelope
response to cell wall acting antibiotics and antimicrobial peptides
Diaz et al.
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(10, 42), and (ii) YycFGHIJ, an essential two-component regula-
tory system characterized in several Gram-positive organisms (in-
cluding E. faecalis) and shown to be involved in cell wall homeo-
stasis and cell division (34, 43, 44, 47).
Our previous work indicated that development of DAP resis-
tance in E. faecalis is a stepwise and ordered process (9, 11, 13).
One distinct pathway involves initial mutations occurring in
genes encoding the three-component regulatory system LiaFSR
followed by changes in genes encoding enzymes involved in phos-
pholipid metabolism (such as CL synthase) (9). Furthermore, we
previously found that a single mutation in liaF of E. faecalis was
sufficient to produce DAP tolerance and that substitutions in
LiaRS were commonly found in E. faecium bloodstream isolates
with MICs of 3 g/ml but absent in isolates with MICs of 2
g/ml (16). In the present study, we expand these observations
and provide several additional lines of evidence to support the
pivotal role of the LiaFSR three-component regulatory system in
the pathway leading to DAP resistance in E. faecium. First, two
substitutions (LiaRW73C and LiaST120A) were commonly found in
unrelated clinical isolates of E. faecium with DAP MICs of 3
g/ml. Moreover, identical changes in these two predicted pro-
teinswere found in two isolates (V689 andP1190)withDAPMICs
of 3g/ml which were recovered in countries where DAP had not
been introduced in clinical practice, suggesting that these muta-
tions can be selected even without DAP exposure, as previously
reported (45). Second, the presence of the same LiaRS substitu-
tions was associated with the DAP-tolerant phenotype, as previ-
ously shown for E. faecalis. Indeed, E. faecium 503, which only
harbors LiaRW73C andLiaST120A andnoother changes in predicted
proteins associated with DAP resistance, behaved as a DAP-resis-
tant isolate in time-kill assays, despite of the fact that its DAPMIC
is within the “susceptible” range. Our findings continue to ques-
tion the stated CLSI DAP breakpoint of 4 g/ml and suggest that
2 g/ml would likely be a better cutoff value if considering DAP
for E. faecium causing deep-seated infections.
Our genomic studies also suggest that a second pathway for
DAP resistance involves changes in the YycFGHIJ system, as pre-
viously observed (15). After LiaFSR, substitutions in this system
were the second most common changes observed in E. faecium
with an MIC of3 g/ml. YycFGHIJ has been implicated in de-
velopment of DAP nonsusceptibility in E. faecium and also in
vancomycin and DAP nonsusceptibility in Staphylococcus aureus
(15, 26, 46). Therefore, it is tempting to speculate that YycFGHIJ is
another important regulatory network that contributes to the re-
sponse to the cell membrane attack by DAP (and possibly other
cell membrane-acting antimicrobials) and may be more relevant
in isolates whose DAP MICs are above the breakpoint. Although
our findings support a role of the YycFGHIJ in DAP nonsuscep-
FIG 2 Time-kill assays with DAP (5 the MIC) with or without AMP (64 g/ml). Bacteria were grown in Mueller-Hinton broth (MHB) supplemented with
calcium (50 mg/liter). The E. faecium strains are indicated at the top of each panel. AMP, ampicillin; DAP, daptomycin. The limit of detection was 200 CFU/ml.
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tibility, direct evidence of such contribution is still lacking and is
the object of our future studies. Further evidence that the LiaFSR
and YycFGHIJ systemsmay lead to distinct pathways in the devel-
opment of DAP resistance comes from our time-kill curve assays
with selected isolates representing each pathway. Recent data sug-
gest that the addition of AMP to DAPmay restore the bactericidal
activity of DAP bymechanisms that are unclear (18, 41). Here, we
show that the synergistic effect of the AMPplusDAP combination
was seen only in isolates representing the LiaFSR pathway (503
and 497) regardless of theMIC, but it was absent with R446 or 515
(DAP-resistant and -susceptible, representing the YycFGHIJ
pathway). These findings suggest that the synergistic effect is de-
pendent on the genetic pathway and that it is not a universal phe-
nomenon seen in all DAP-nonsusceptible E. faecium, a finding
with important therapeutic implications.
Our data using the fluorescent derivative BDP-DAP also pro-
vide evidence that in DAP-nonsusceptible isolates (MICs above
the E. faecalis breakpoint), reduced binding of the antibiotic mol-
ecule from the surface appears to be the main mediator of resis-
tance regardless of the mutational pathway. However, specific ge-
netic changes also seem to affect the interaction of DAP with the
cell membrane in isolates with MICs below the breakpoint that
exhibit DAP tolerance. Indeed, in E. faecium 503 (DAP MIC 3
g/ml) binding of BDP-DAP did not differ from that of DO (con-
trol) even at high antibiotic concentrations, similar to what it has
been shown previously in E. faecalis (8). Thus, it is tempting to
speculate that in E. faecium 503, LiaFSR-mediated “diversion” of
DAP from lethal target sites (i.e., septum) is pivotal for the DAP
tolerance phenotype. It is important to note that changes in these
systems may not be mutually exclusive since two strains with mu-
tations in both YycFGHIJ and LiaFSR were identified, adding
complexity to the genetic changes associated with DAP resistance.
Finally, our findings also support our previous hypothesis that
changes in phospholipid enzymes are common among DAP-re-
sistant E. faecium and are likely to be associated with later stages of
development of DAP resistance. In E. faecium, changes in CL syn-
thase seem to be the prevailing “route” in isolates with high DAP
MIC although changes in this enzyme were not found in all iso-
lates. We had previously shown that mutations in the predicted
Cls active site appear to increase the catalytic activity of the en-
zyme (36), whichmay be sufficient to optimize theDAP resistance
phenotype. Although changes in many other predicted proteins
were found, we speculate that these changes may play a less im-
portant role in the mutational sequence and may be minor con-
tributors since they were found in small number of isolates. The
role of these proteins in DAP resistance remains to be elucidated.
In summary, we provide genomic evidence that two major
pathways (LiaFSR and YycFGHIJ) appear to be the most impor-
tant changes associated with development of DAP resistance in E.
faecium clinical isolates. Although the sequence of mutations ap-
pear to be complex, initial changes in regulatory systems that con-
trol the cell envelope response to stress may be of paramount
importance to fully develop DAP resistance. Our findings also
open the possibility of using genotypic information to identify
FIG 3 BODIPY-labeled DAP (BDP-DAP) staining of E. faecium strains. (A) Fluorescence intensities of representative E. faecium strains. Cells were treated with
BDP-DAP and fluorescence was normalized to cell protein content. Intensities were compared to E. faeciumDO. Rfu, relative fluorescence units; *, P 0.05; **,
P  0.001; NS, not significant. (B) BDP-DAP staining of representative E. faecium cells at concentrations of 4 g/ml and 64 g/ml. The top images capture
bacterial cells under fluorescence microscopy (bars, 1 m). The bottom images are the same bacterial cell in phase contrast. The mutated pathway is indicated
in parentheses.
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isolates that are likely to fail DAP therapy in vivo and those in
which the combination of DAP plus -lactams may be effective.
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